Log in

Relevant bibliographies by topics / Bečva / Journal articles

To see the other types of publications on this topic, follow the link: Bečva.

Journal articles on the topic 'Bečva'

Author: Grafiati

Published: 4 June 2021

Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Bečva.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mackovík, Leo, Ivo Sukop, Miloš Holzer, and Petr Spurný. "Hydrobiological study of the middle course of the Bečva River." Acta Universitatis Agriculturae et Silviculturae Mendelianae Brunensis 58, no. 4 (2010): 159–66. http://dx.doi.org/10.11118/actaun201058040159.

Full text

Abstract:

The present work gives the results of the hydrobiological research of the middle course of the Bečva River in the river section between Valašské Meziříčí and Přerov, carried out in the years 2004 to 2007. Altogether, 65 taxa of macrozoobenthos were determined in the period 2000-2007 in the middle course of the Bečva River : Coelenterata (1 taxon), Oligochaeta (5 taxa), Hirudinea (3 taxa), Gastropoda (4 taxa), Isopoda (1 taxon), Amphipoda (2 taxa), Hydracarina (1? taxon), Ephemeroptera (7 taxa), Plecoptera (1 taxon), Odonata (3 taxa), Heteroptera (1 taxon), Megaloptera (1 taxon), Trichoptera (9 taxa), Coleoptera (3 taxa), Diptera (23 taxa). The number of zoobenthos taxa fell in the period 2004–2007 in comparison to period 2000–2002 from 51 taxa to 40 taxa. The decline of zoobenthos taxa was registered on study localities, as follows : Choryně (from 28 to 23 taxa), Hustopeče (from 27 to 25 taxa), Rybáře (from 35 to 28 taxa), Grymov (from 31 to 25 taxa). Average saprobity index of benthic community of the middle course of the Bečva River was 2.35. Average saprobity indices of monitored localities towards downstream were as follows: Choryně 2.41; Hustopeče 2.25; Rybáře 2.40; Grymov 2.34.

APA, Harvard, Vancouver, ISO, and other styles

2

I Namin, J., and P. Spurný. "Fish community structure of the middle course of the Bečva River." Czech Journal of Animal Science 49, No. 1 (December 11, 2011): 43–50. http://dx.doi.org/10.17221/4270-cjas.

Full text

Abstract:

Fish communities of the Bečva River were studied in summer and autumn 2000 and 2001. Electric fishing gear (Honda EX 1000, DC 230 V, 0.75–0.9 kW) was used for sampling. Four sampling sites (Grymov 19.6 r. km, Rybáře 35.8 r. km, Hustopeče 50.7 and Choryně 54.7 r. km) were selected. Total of 23 fish species representing 5 families were determined. The family Cyprinidae with 15 species was dominant while Salmonidae, Balitoridae, Percidae and Gadidae were the other recorded families. Species diversity ranged from 9 at Hustopeče to 20 at Grymov localities. The lowest biomass and abundance were observed at Hustopeče locality (28.93 kg/ha and 336 fishes/ha) and the highest at Choryně locality (612.90 kg/ha and 7 367 fishes/ha). Barbus barbus, Chondrostoma nasus and Leuciscus cephalus contributed 87.73–97.55% and 60.5%–87% to total biomass and abundance in different samplings, respectively. The Chondrostoma nasus population was dominated by fish of total length over 300 mm. We believe that river fragmentation, trapping and blockade of fish are the main reasons for this irregular distribution. Index of diversity ranged from 0.811 to 2.05 and equitability index from 0.449 to 0.821. Physical and chemical parameters were also measured, pH value ranged from 7.8 to 9.8, DO (7.62–12.15 mg/l), conductivity (450–639 µS/cm), N-NH<sub>4</sub> (0.65–2.39 mg/l), P-PO<sub>4</sub> (0.12–0.68 mg/l)and alkalinity (2.55 to 3.40 mg/l).  

APA, Harvard, Vancouver, ISO, and other styles

3

Vikhrov, Dmytro, Robert Stojanov, Barbora Duží, and David Juřička. "Commuting patterns of Czech households exposed to flood risk from the Bečva river." Environmental Hazards 13, no. 1 (January 2, 2014): 58–72. http://dx.doi.org/10.1080/17477891.2013.864593.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Stacke, Václav, Tomáš Pánek, and Jan Sedláček. "Late Holocene evolution of the Bečva River floodplain (Outer Western Carpathians, Czech Republic)." Geomorphology 206 (February 2014): 440–51. http://dx.doi.org/10.1016/j.geomorph.2013.10.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Klečka, J. "Early stadiums of floodplain forest succession in a wide river beds upon an example of Bečva." Journal of Forest Science 50, No. 7 (January 11, 2012): 338–52. http://dx.doi.org/10.17221/4631-jfs.

Full text

Abstract:

In the years 1999–2001 early stadiums of succession development of a floodplain forest were monitored in the wide bed of the Bečva River formed during the floods in 1997. Changing site conditions were investigated and the vegetation of pebble beds was repeatedly mapped in detail. In dependence on the site conditions main types of biotopes were described. The vegetation data were evaluated in accordance with the life form and ecological claims of the identified species. The results indicated an increasing differentiation of the originally relatively homogeneous environment owing to fluvial processes and progress of vegetation. Generally hemicryptophytes and hemiheliophytes were thriving above all, the dominance of Phalaris arundinacea was still growing. As for the woody species, especially willows asserted themselves from the beginning, solitarily and weaker in vitality representatives of other genera were present at drier sites. The identified specimen of Myricaria germanica was probably planted artificially. As concerns neophytes, only Reynoutria japonica was spreading significantly but in a very uneven way. Generally, this development of similar communities only little documented in this region corresponds to STG Saliceta fragilis inf.

APA, Harvard, Vancouver, ISO, and other styles

6

Kyncl, M., R. Heiduk, and S. Heviánková. "Possibilities of application of artificial groundwater recharge in the catchment areas of the Odra and Bečva rivers." IOP Conference Series: Earth and Environmental Science 92 (October 2017): 012035. http://dx.doi.org/10.1088/1755-1315/92/1/012035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kolář, Tomáš, and Michal Rybníček. "Physical and mechanical properties of subfossil oak (Quercus, sp.) wood." Acta Universitatis Agriculturae et Silviculturae Mendelianae Brunensis 58, no. 4 (2010): 123–34. http://dx.doi.org/10.11118/actaun201058040123.

Full text

Abstract:

The paper deals with the examination of physical and mechanical properties of subfossil wood of oak (Quercus, sp.). The issue of establishing physical and mechanical properties of subfossil oak wood has not yet been addressed in the area of the Czech Republic. The main objective is to find out what changes to subfossil wood properties have occurred in comparison with recent wood. For these purposes, samples from three locations were taken (gravel pit Tovačov – district Přerov, gravel pit Kostomlátky – district Nymburk, and the Bečva basin near Osek nad Bečvou). All of the selected properties were tested in compliance with relevant valid Czech technical norms (ČSN). The results provide us with a realistic picture of the properties of wood that has been deposited under the ground in very specific conditions for thousands of years. With regard to density, the results do not show any definite changes. The dimensions of subfossil wood are approximately doubled in comparison with recent wood. On the other hand, there is an obvious decrease in mechanical properties. The paper also offers the results of dendrochronological or radiocarbon dating of the trunks.

APA, Harvard, Vancouver, ISO, and other styles

8

Škarpich, Václav, Tomáš Galia, Stanislav Ruman, and Zdeněk Máčka. "Variations in bar material grain-size and hydraulic conditions of managed and re-naturalized reaches of the gravel-bed Bečva River (Czech Republic)." Science of The Total Environment 649 (February 2019): 672–85. http://dx.doi.org/10.1016/j.scitotenv.2018.08.329.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Baran, R., J. Kubecka, M. Kubín, B. Lojkásek, T. Mrkvička, D. Ricard, and M. Rulík. "Abundance of Cottus poecilopus is influenced by O2 saturation, food density and Salmo trutta in three tributaries of the Rožnovská Bečva River, Czech Republic." Journal of Fish Biology 86, no. 2 (December 31, 2014): 805–11. http://dx.doi.org/10.1111/jfb.12565.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Fránková, Markéta, Aloisie Poulí Ková, Jiří Neustupa, Martina Pichrtová, and Petr Marvan. "Geometric morphometrics - a sensitive method to distinguish diatom morphospecies: a case study on the sympatric populations of Reimeria sinuata and Gomphonema tergestinum (Bacillariophyceae) from the River Bečva, Czech Republic." Nova Hedwigia 88, no. 1 (February 1, 2009): 81–95. http://dx.doi.org/10.1127/0029-5035/2009/0088-0081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Zhou, Xiaoling, Jianbin Qin, Chuan Xiao, Wei Wang, Xuemin Lin, and Yoshiharu Ishikawa. "BEVA." ACM Transactions on Database Systems 41, no. 1 (April 7, 2016): 1–44. http://dx.doi.org/10.1145/2877201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Walter, F., N. Lid, F. Petermann, and A. Kobelt. "Einsatz des Beschwerdenvalidierungstests BEVA in der sozialmedizinischen Begutachtung." Die Rehabilitation 56, no. 03 (April 3, 2017): 173–80. http://dx.doi.org/10.1055/s-0042-121370.

Full text

Abstract:

Zusammenfassung Die vorliegende Studie ermittelt, inwiefern der BEVA als Screening geeignet ist, um negative Antwortverzerrungen bei Rentenantragstellern mit psychosomatischen Erkrankungen in der sozialmedizinischen Begutachtung zu erfassen. 107 Versicherte, die eine Erwerbsminderungsrente aufgrund einer psychosomatischen Erkrankung beantragt haben, füllten den BEVA, den SFSS sowie einen soziodemografischen Fragebogen aus. Die sozialmedizinischen Gutachter schätzen die Glaubwürdigkeit der Beschwerdendarstellung der Versicherten ein. Es wurde ein Known-Group-Design bzw. ein Bootstrapping-Design genutzt, um die Validität des BEVA zu schätzen. Bei dem Außenkriterium SFSS konnten folgende psychometrische Kennwerte für den BEVA ermittelt werden: Spezifität=0,86, Sensitivität=0,42, positiv prädiktiver Wert=0,81, negativ prädiktiver Wert=0,51. Die Interrater-Reliabilität entspricht Cohens κ=0,253. Für die Gutachtereinschätzung als Außenkriterium konnten weitere psychometrische Kennwerte berechnet werden: Spezifität=0,71, Sensitivität=0,32, positiv prädiktiver Wert=0,38, negativ prädiktiver Wert=0,66. Die Beurteilerübereinstimmung beträgt Cohens κ=0,031. Die Ergebnisse verdeutlichen, dass der BEVA vor allem eine sehr gute Spezifität aufweist, um negative Antwortverzerrungen zu erheben. Dies ist im Hinblick auf ethische Aspekte dringend anzustreben. Weiterhin zeigt die Studie, dass - neben den Gutachtereinschätzungen – weitere Verfahren die Erkennung von negativen Antwortzerrungen verbessern könnten.

APA, Harvard, Vancouver, ISO, and other styles

13

Bainbridge, R. "BEVA Congress - Cambridge." Equine Veterinary Education 3, no. 4 (December 1991): 241–42. http://dx.doi.org/10.1111/j.2042-3292.1991.tb01534.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Vanneuville, A., J. Gentil, C. Vautravers-Dewas, S. Guiu, L. Favier, S. Causeret, F. Mayer, B. Coudert, and P. Fumoleau. "Bevacizumab combined with taxanes in second-line or more for metastatic breast cancer: Efficacy and predictive factors of response." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 1122. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.1122.

Full text

Abstract:

1122 Background: In metastatic breast cancer (MBC), bevacizumab (BEVA) and taxanes (TAX) (paclitaxel or docetaxel) are very efficient as first line metastatic therapy. However, such combination is questionable in subsequent lines of therapy. Aims: evaluate the efficacy and the factors of response of BEVA and TAX combination in second line or more for MBC. Methods: A retrospective study was done on all the MBC patients treated with BEVA combined with TAX, between July 2007 and November 2008, in the medical oncology department. Statistics were descriptive for the population and the efficacy. Univariate and multivariate analysis were used to determine the predictive factors of response. Results: 31 patients received BEVA combined with paclitaxel in 30 cases (96.7%) or docetaxel in one case (3.3%). Mean age was 55.3 years (IC95% [50.8–59.7]). Median number of previous lines was 4 (range [2–10]). 14 patients had already progressed under TAX therapy. Mean follow up was 7.1 months (IC 95% [5.9–8.4]). Thirteen (41.9%) patients had a clinical response, partial in 12 (38.7%) and complete in 1 (3.2%) patients. Four (12.9%) additional patients were stabilized therefore clinical benefit (CR+PR+SD) was obtained in 17 (60.7%) patients. The mean duration of the clinical benefit, measured as the delay between the first day of BEVA-TAX treatment and the date of progression or last news date, was of 5.8 months (IC95% = [4.4–7.1]). The progression delay, for patients who presented a progression and needed the introduction of a new therapy, was of 2.4 months (IC95% = [1.7–3.1]). Eleven (35.5%) patients had no clinical benefit and readily progressed under therapy. Multivariate analysis showed that age less than 65 (OR = 14.5 IC95% = [1.6–128.7]; p = 0.016) and a number of previous lines less than 6 (OR = 11.0 IC95% = [1.2–102.7]; p = 0.036) were related to the clinical benefit. Previous TAX resistance had no significant influence on the efficacy of the combination. Conclusions: In pretreated MBC patients, the combination of BEVA and TAX can be effective with a mean duration of clinical benefit around 6 months. Age over than 65 and a number of previous lines over 5 could be considered as factors of resistance to such a combination. These results have to be confirmed in larger studies. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

15

Milano, Gerard A., Jean-Yves Pierga, Jocelyn Gal, Laurence Llorca, Coraline Dubot, Gilles Romieu, Isabelle Desmoulins, et al. "Pharmacogenetics revisits bevacizumab in breast cancer patients: An ancillary analysis of the UCBG trial COMET—A French multicentric prospective study from R&D UNICANCER." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 1079. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.1079.

Full text

Abstract:

1079 Background: Bevacizumab (Beva) is no longer unanimously recommended in the management of breast cancer (BC). Given the absence of faithful predictors of Beva treatment outcome, we made the hypothesis that constitutional gene polymorphisms could play a role in this context. We report the pharmacogenetic ancillary study of the prospective COMET trial conducted in advanced BC patients (pts) receiving first-line Beva associated with paclitaxel. Methods: Relevant targeted gene polymorphisms were analyzed (blood) in 203 prospective pts (mean age 55.3, median follow-up 24 months). VEGFA at positions -2578C > A (rs699947), -1498T > C (rs833061), -634G > C (rs2010963), and 936C > T (rs3025039) were analyzed by PCR-RFLP. VEGFR1 319A > C (rs9582036), VEGFR2 at positions 604C > T (rs2071559), 1192C > T (rs2305948), 1416T > A (rs1870377), IL8 251T > A (rs4073), CYP2C8 139C > T (rs1572080), 399T > C (rs10509681) and ABCB1 at positions 1199 C > TA (rs2229109), 2677G > TAC (rs2032582) were analyzed by Mass-Array Agena. ABCB1 1236C > T (rs1128503) and 3435T > C (rs1045642) were analyzed by pyrosequencing. All fitted HWE. Results: Median progression-free survival (PFS) was 10.8 months. VEGFR1 319A allele was associated with longer PFS (p = 0.03). The VEGFA-1498T allele was significantly associated with both longer overall survival (OS) (p = 0.005) and PFS (p = 0.065). The VEGFA -2578C allele was associated with greater OS (p = 0.002) and PFS (p = 0.071). These two VEGFA polymorphisms were in linkage disequilibrium (p < 0.0001). Multivariate Cox analysis showed that VEGFA -2578 (p = 0.001) and VEGFR2 1416 (p = 0.025) were significant predictors of OS: the score of favorable alleles (VEGFA -2575C and VEGFR2 1416T) was highly associated with OS (p = 0.0003), with median survival at 24 months being 30% for score 0 (95%CI 15-61), 65% for score 1 (95%CI 55-75) and 90% for score 2 (95%CI 67-90). Conclusions: Application of an easy-to-perform low-cost genotyping test may identify strong predictors of Beva outcome in metastatic BC pts. In the current era of precision medicine, a pharmacogenetic-based personalized Beva therapy deserves to be prospectively validated in BC pts. Clinical trial information: 2012-A00244-39.

APA, Harvard, Vancouver, ISO, and other styles

16

Privitera, G., C. Spatola, G. Acquaviva, G. Di Franco, R. Salvo, L. Raffaele, V. Salamone, and G. Ettorre. "Addition of bevacizumab (beva) to xeliri/xelox chemoradiotherapy in neoadjuvant setting for patients (pts) with locally advanced rectal cancer (LARC): A feasibility study." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 14583. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14583.

Full text

Abstract:

14583 Background: Preoperative chemo-radiotherapy in pts with LARC has been extensively evaluated, although no standard treatment has been defined. We planned to add the new anti-VEGF monoclonal antibody bevacizumab in the neoadjuvant setting, in order to evaluate whether the modifications induced in normal and tumor microcirculation and vascularity could increase the treatment toxicity profile and induce relevant complications during the surgery. Methods: From Jul 05 to Sept 06, pts with histologically proven uT3–4 N± or uT2 N+ rectal cancer were treated with capecitabine 1,000 mg/m2 bid on days 1–14 before chemoradiation phase and then 825 mg/m2 bid on days 22–55 plus irinotecan 180 mg/m2 (XELIRI) or oxaliplatin 130 mg/m2 (XELOX) on days 1, 22, 43 in combination with BEVA 5 mg/kg q2w starting on day 1 until the completion of the treatment. Radiotherapy was administered according to our previous study (45 Gy to the whole pelvis, plus 9 Gy as conc. boost to the CTV during the last six fractions). Surgery was carried out 8 weeks after the completion of chemoradiation. Results: Eleven pts (7 male/4 female), ECOG PS 0–1, were enrolled in this study. No patient showed systemic disease at the time of diagnosis. Six pts received XELIRI chemotherapy, 5 pts XELOX. Ten pts completed the planned chemotherapy schedule, one patient discontinued chemotherapy administration after the second irinotecan infusion due to GI grade III toxicity. All eleven pts completed the planned radiation treatment, with a total dose of 54 Gy. Three pts reported moderate hypertension, treated with standard anti-hypertensive drugs, and one had epistaxis, but no one required discontinuation of BEVA Conclusions: The use of BEVA in the neoadjuvant setting of pts with LARC is feasible and safe. In combination with XELIRI/XELOX chemoradiation, BEVA does not increase the treatment toxicity profile, nor provoke any surgical delay or modifications. BEVA in this setting should be further evaluated in larger phase II studies, in order to estimate the rates of clinical and pathologic complete and partial response, compared to XELIRI/XELOX chemoradiation schedules. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

17

Eveno, Clarisse, Guillaume Passot, Diane Goéré, Philippe Soyer, Etienne Gayat, Olivier Glehen, Dominique Elias, and Marc Pocard. "Bevacizumab before cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin: Analysis of early postoperative complication rate and long term follow-up." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 3642. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3642.

Full text

Abstract:

3642 Background: Patients with stage IV colorectal cancer and peritoneal carcinomatosis are increasingly treated with curative intent and perioperative systemic chemotherapy combined with targeted therapy.The aim of the study was to analyze the potential impact of bevacizumab on early morbidity and survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis of colorectal origin. Methods: From 2004 to 2010, in three referral centers, 182 patients with colorectal carcinomatosis were treated with complete cytoreduction followed by HIPEC after either preoperative systemic chemotherapy alone or in combination with bevacizumab. Because there was no control on treatment allocation, propensity score methods were used to control this bias. Results: The median time from discontinuation of bevacizumab to HIPEC was 7 weeks (range, 6-10). Major morbidity was greater in the Beva group (34 vs. 19%, p=0.020). Nine patients died postoperatively: 5 (6.2%) in the Beva group (n=80) and 4 (3.9%) in the group treated with chemotherapy alone (n=102) (p=NS). The rate of digestive fistulas was greater in the Beva group, although not significant (18 vs. 10%, p=NS). After matching, the effect of Bevacizumab on major morbidity (including death) was found to be significant (OR = 2.28, 95% CI; 1.05 - 4.95) (p=0.04). No difference in median of overall and disease free survival was found between the two groups (12 and 36 month in Beva group vs. 14.3 and 49 month in the control group, p=NS). Conclusions: Administration of bevacizumab before surgery with complete cytoreduction followed by HIPEC for colorectal carcinomatosis is associated with 2-fold increased morbidity. The oncologic benefit of bevacizumab before HIPEC remains to be evaluated with prospective randomized study.

APA, Harvard, Vancouver, ISO, and other styles

18

Vaccaro, V., F. Cuppone, F. Loupakis, M. Milella, P. Carlini, C. Nisticò, A. Falcone, E. Terzoli, F. Cognetti, and E. Bria. "Magnitude of benefit of the addition of bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e15021-e15021. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e15021.

Full text

Abstract:

e15021 Background: The monoclonal antibody against vascular endothelial growth factor BEVA has recently demonstrated to improve survival for MRC patients (pts). Nevertheless, the magnitude of the provided benefit in the daily practice is still controversial. In order to quantify the benefit of adding BEVA to CT for MCRC, a literature-based meta-analysis was conducted. Methods: Survival Hazard Ratios (HR) were extracted from prospective, randomized clinical trials (RCTs, either phase II/III) reports. HR and event-based relative risks (RR) with 95% confidence intervals (CI) were derived through a random-effect model. Differences in primary (progression-free- and overall-survival, PFS/OS) and secondary outcomes (overall, partial and complete response rates, ORR/PR/CR) were explored. Absolute differences (AD) and the number of patients needed to treat (NNT) were calculated. Heterogeneity test and a meta-regression analysis with clinical predictors for outcomes were conducted as well. A sensitivity analysis according to the trial phase-design was accomplished. Results: Five trials (2,728 pts), 2 phase II (313 pts) and 3 phase III (2,415 pts), were gathered. No significant interaction was found in the sensitivity analysis between phase II and III, although a trend showed a better PFS results for BEVA in phase II trials (p=0.057). At the meta-regression analysis female gender and rectal primary site were significant predictors for PFS (p=0.003, p=0.005). Toxicity analysis is ongoing. Conclusions: Although concerns regarding costs and toxicities still exist, BEVA significantly improves the outcome of untreated MCRC pts. The absolute benefit provided into an unselected population for molecular features should be considered of paramount importance for advanced disease. [Table: see text] No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

19

Indriyani, Nori, and Rahmi Munfangati. "Emotional intelligence in Belva Plain’s Blessings." EduLite: Journal of English Education, Literature and Culture 4, no. 2 (September 4, 2019): 204. http://dx.doi.org/10.30659/e.4.2.204-215.

Full text

Abstract:

Everyone faces emotional challenges. It can influence their behavior since emotion is an incredibly strong drive on human behavior. This powerful emotion can lead someone to take actions that he might not regularly do, or keep away from the conditions that someone enjoys. Emotionality is related to a range of psychological phenomena, including mood, temperament, personality, and motivation. The ability to control emotions in the self and others is called Emotional Intelligence (EI). EI can be found not only in real life but in literary works such as a novel. In line with that interesting topic, this article, therefore, explores the EI and the implications of EI of the main character in Belva Plain’s Blessings. In analyzing the novel, the study applied a psychological approach. The technique of analyzing the data was a qualitative descriptive method. The findings of the study showed Jennie’s EI, that is composed of emotional self-awareness, self-regulation, motivation, and social skills. Furthermore, the results revealed the implications of Jennie’s EI; she becomes successful because she is good at self-regulation and motivation. She is also good at self-awareness, empathy and social skills, so she has better interpersonal relations.

APA, Harvard, Vancouver, ISO, and other styles

20

Walter, Franziska, Lena Döhring, and Axel Kobelt-Pönicke. "Die Erfassung der Beschwerdenvalidität von psychischen Störungen: Die diagnostische Güte des SFSS im Vergleich zum BEVA." Zeitschrift für Psychiatrie, Psychologie und Psychotherapie 68, no. 2 (March 2020): 70–80. http://dx.doi.org/10.1024/1661-4747/a000406.

Full text

Abstract:

Zusammenfassung. Die vorliegende Studie ermittelt, ob der Beschwerdenvalidierungstest SFSS als Screening geeignet ist, um negative Antwortverzerrungen bei Patient_innen mit psychischen Störungen zu erfassen. Darüber hinaus soll die Interrater-Reliabilität des SFSS und einem weiteren Beschwerdenvalidierungstest – dem BEVA – für unterschiedliche Cut-Off-Werte des SFSS analysiert werden. Die Stichprobe ( N = 187) besteht aus Patient_innen mit einer Depression, einer gesunden Kontrollgruppe und Instruierten Simulant_innen. Das Analogstudiendesign wurde genutzt, um die Gruppenunterschiede im Gesamtwert des SFSS, den Cut-Off-Wert des SFSS, die diagnostische Güte des SFSS und die Übereinstimmung von SFSS und BEVA zu überprüfen. Die Ergebnisse zeigten, dass sich die Gruppen im Gesamtwert des SFSS signifikant unterscheiden. Die Instruierten Simulant_innen wiesen den höchsten, die Teilnehmenden der gesunden Kontrollgruppe den niedrigsten Gesamtwert im SFSS auf. Anhand der Daten der Instruierten Simulant_innen und der klinischen Stichprobe konnten mithilfe einer ROC-Analyse zwei mögliche Cut-Off-Werte für den SFSS ermittelt werden. Bei einem Cut-Off-Wert von 18 beträgt die Sensitivität .87, die Spezifität .45, der positiv prädiktive Wert .60 und der negativ prädiktive Wert .79. Für den Cut-Off-Wert von 24 können folgende Werte ermittelt werden: Eine Sensitivität von .62, eine Spezifität von .78, ein positiv prädiktiver Wert von .72, ein negativ prädiktiver Wert von .68. Die höchste Interrater-Reliabilität für den SFSS und BEVA kann für einen Cut-Off-Wert im SFSS von 24 berechnet werden (κ = .478). Der Cut-Off-Wert des SFSS sollte für den klinischen Kontext angepasst werden. Die Ergebnisse zeigten jedoch, dass der SFSS als ein sensitives Screening eingesetzt werden kann. Da der BEVA ein sehr spezifisches Verfahren darstellt, konnte die höchste Übereinstimmung mit dem SFSS bei einem Cut-Off-Wert von 24 erreicht werden. Die Verfahren könnten im klinischen Kontext gemeinsam angewendet werden, um die Diagnostik von negativen Antwortverzerrungen weiterhin zu verbessern.

APA, Harvard, Vancouver, ISO, and other styles

21

Kobelt-Pönicke, Axel, Franziska Walter, Naina Lid, and Nadia Ramien. "Zum Einfluss einer Ehrlichkeitserklärung auf die Authentizität von Beschwerdedarstellungen." Die Rehabilitation 59, no. 05 (August 31, 2020): 291–97. http://dx.doi.org/10.1055/a-1195-7986.

Full text

Abstract:

Zusammenfassung Theoretischer Hintergrund Unehrliches Antwortverhalten von Rentenantragstellern während der Begutachtung wird von impliziten Motiven moderiert. Menschen handeln dann eher unehrlich, wenn sie dafür ihr positives Selbstbild nicht aufgeben müssen. Fragestellung Führt eine Ehrlichkeitserklärung zu Beginn einer sozialmedizinischen Begutachtung zu einer Verringerung unehrlichen Antwortverhaltens? Methode 248 Rentenantragsteller wurden auf zwei Begutachtungsarme (Ehrlichkeitserklärung) vor oder nach Testbearbeitung von 2 Beschwerdevalidierungstests (SFSS, BEVA)) randomisiert. Ergebnisse Die Ehrlichkeitserklärung wirkte sich auf den SFSS, nicht jedoch auf den BEVA aus. Der Effekt war von der Schulbildung abhängig. Schlussfolgerung Bei der Beurteilung von Antwortverzerrungen in Begutachtungen müssen latente moralische und soziale Motive in der Anamnese berücksichtigt werden. Höher Gebildete bevorzugen andere moralische Standards oder gehen situationsabhängig individueller mit moralisch herausfordernden Situationen um.

APA, Harvard, Vancouver, ISO, and other styles

22

Kaminski, Alexandra, Thomas Merten, and Axel Kobelt-Pönicke. "Der Vergleich von drei Beschwerdenvalidierungstests in der stationären psychosomatischen Rehabilitation." Zeitschrift für Psychiatrie, Psychologie und Psychotherapie 68, no. 2 (March 2020): 96–105. http://dx.doi.org/10.1024/1661-4747/a000408.

Full text

Abstract:

Zusammenfassung. Hintergrund: Innerhalb der medizinisch-beruflich orientierten Rehabilitation besteht ein Teilauftrag in der sozialmedizinischen Begutachtung der Rehabilitand_innen. Verzerrte Beschwerdenangaben können die Behandlung und gutachtliche Beurteilung erheblich erschweren. Zur Validierung geltend gemachter Beschwerden stehen fragebogenbasierte Beschwerdenvalidierungstests (BVT) zur Verfügung, welche jedoch in Rehabilitationsstudien Studien nur wenig eingesetzt werden. Ziel der vorliegenden Studie ist es daher, drei BVTs in einer klinischen Stichprobe aus der psychosomatischen Rehabilitation anzuwenden. Der Anteil von Proband_innen, die als unzuverlässig in ihrer Beschwerdenschilderung einzustufen sind, soll berichtet und die drei BVTs sollen miteinander verglichen werden. Methode: Daten von 147 psychosomatischen Rehabilitand_innen werden berichtet. Alle Proband_innen beantworteten unter anderem den Beschwerdenvalidierungstest (BEVA), das Self-Report Symptom Inventory (SRSI) und den Strukturierten Fragebogen Simulierter Symptome (SFSS). Ergebnisse: Der Anteil der Rehabilitand_innen, bei denen die Verfahren eine verzerrte Beschwerdenschilderung auswiesen, lag bei ca. 35 %. Die Korrelation zwischen dem BEVA und dem SRSI betrug 0.82. Die Korrelation des SFSS mit dem BEVA lag bei 0.65 und mit dem SRSI bei 0.72. Schlussfolgerung: Die Ergebnisse weisen aus, dass ca. 35 % der Stichprobe extreme, atypische oder bizarre Symptome in einer Weise bejahten, dass ihre Beschwerdenschilderungen als unzuverlässig, überhöht und / oder ausgeweitet bewertet werden mussten. Demnach bekräftigt die vorliegende Studie das Einsetzen von Beschwerdenvalidierungsinstrumenten im sozialmedizinischen Kontext. Die drei vorgelegten BVTs korrelierten hoch miteinander, so dass darauf zu schließen ist, dass sie das gleiche und / oder ein ähnliches Konstrukt messen.

APA, Harvard, Vancouver, ISO, and other styles

23

Eveno, Clarisse, Olivier Glehen, Diane Goéré, Anne-Claire Lukaszewicz, Guillaume Passot, Dominique Elias, and Marc Pocard. "Influence of bevacizumab on early postoperative complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin." Journal of Clinical Oncology 30, no. 4_suppl (February 1, 2012): 601. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.601.

Full text

Abstract:

601 Background: Increasingly patients with IV stage colorectal cancer received systemic chemotherapy combined with targeted therapy among which bevacizumab. In neoadjuvant situation, a delay of at least 6 weeks between discontinuation of bevacizumab and surgery is recommended, not to increase the risk of complications (delayed healing, bleeding) related to bevacizumab. The goal of this study was to analyze the potential impact of bevacizumab on early morbidity after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis of colorectal origin. Methods: From 2004 to 2010, in three hospitals, 183 patients treated with complete cytoreduction followed by HIPEC for colorectal carcinomatosis, received preoperative treatment. It was either systemic chemotherapy alone (Chemo group, n = 100) or by chemotherapy combined with bevacizumab (Beva group, n = 83). Results: Both patient groups were comparable in the extent of carcinomatosis, assessed on peritoneal cancer index means (10.4 vs 10, p> 0.05), number of resected organs (4.3 vs 3.8, p> 0.05), operative time (420 vs. 380 minutes, p> 0.05) and volume of blood loss (470 vs 510ml, p> 0.05). The median time from discontinuation of bevacizumab and HIPEC was 7 weeks (6-10), always greater than 6 weeks. Nine patients postoperatively died, 4 (4%) in the chemo group and 5 (6%) in the beva group (ns). Grade 3 to 5 complication rate was higher in the beva group (25 vs 12%, p <0.05). Whatever the hospital, complications that may be related to bevacizumab occurred more frequently in patients in the beva group: with more digestive fistulas (18 vs 8%, p <0.05), deep abscesses (13 vs 3 %, p <0.01) and delayed healing (11 vs 2%, p <0.02). Conclusions: Administration of bevacizumab before surgery with complete cytoreduction followed by HIPEC for carcinomatosis colorectal is associated with increased morbidity, probably due to multiple organ resections performed during the surgery. The oncologic benefit of bevacizumab before HIPEC remains to be evaluated.

APA, Harvard, Vancouver, ISO, and other styles

24

Kobelt-Pönicke, Axel, Franziska Walter, and Mario Riemann. "Führt das Bewusstsein moralischer Grundwerte zu einem authentischeren Antwortverhalten in Beschwerdenvalidierungstests?" Zeitschrift für Psychiatrie, Psychologie und Psychotherapie 68, no. 2 (March 2020): 106–12. http://dx.doi.org/10.1024/1661-4747/a000409.

Full text

Abstract:

Zusammenfassung. Hintergrund: Menschen rechtfertigen unehrliches Verhalten, um das subjektive Selbstbild nicht zu gefährden. Die Rechtfertigung muss dabei so überzeugend sein, dass moralische Grundwerte in den Hintergrund treten. Der hohe Anteil auffälliger Beschwerdenvalidierungstests in Begutachtungssituationen weist darauf hin, dass die subjektive Überzeugung, keiner Arbeitstätigkeit mehr nachgehen zu können, die moralische Verpflichtung zur authentischen Beschwerdenschilderung außer Kraft setzt. Fragestellung: Führt die Bewusstmachung moralischer, an Gerechtigkeit und Ehrlichkeit orientierter Werte zu Beginn einer sozialmedizinischen Begutachtung zu einer Verringerung unehrlichen Antwortverhaltens in Beschwerdenvalidierungstests? Methode: 93 Rentenantragsteller_innen wurden auf zwei Begutachtungsarme (mit und ohne Aktualisierung moralischer Werte vor der Bearbeitung von Beschwerdevalidierungstests (SFSS, BEVA) randomisiert. Ergebnisse: Die Bewusstmachung moralischer Werte, die an Gerechtigkeit, Ehrlichkeit und Rechtsempfinden appellieren, wirkte sich auf den BEVA, nicht jedoch auf den SFSS aus. Schlussfolgerung: Die Bewusstmachung moralischer Werte fördert ein authentisches Antwortverhalten. Der Effekt ist möglicherweise vom Grad des individuellen Bewusstseins über das eigene Täuschungsverhalten abhängig.

APA, Harvard, Vancouver, ISO, and other styles

25

Bowen, I. M., A. Redpath, A. Dugdale, J. H. Burford, D. Lloyd, T. Watson, and G. D. Hallowell. "BEVA primary care clinical guidelines: Analgesia." Equine Veterinary Journal 52, no. 1 (December 10, 2019): 13–27. http://dx.doi.org/10.1111/evj.13198.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Dyson, S. J. "News from BEVA AGM (Scientific) 1993." Equine Veterinary Education 6, no. 2 (April 1994): 78–79. http://dx.doi.org/10.1111/j.2042-3292.1994.tb01093.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hangartner, H. "Nursing Sessions BEVA 2002: an overview." Equine Veterinary Education 14, no. 6 (January 5, 2010): 282–83. http://dx.doi.org/10.1111/j.2042-3292.2002.tb00188.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Mitchell, Colin. "BEVA report: making the business enjoyable." UK-Vet Equine 2, no. 6 (November 2, 2018): 166. http://dx.doi.org/10.12968/ukve.2018.2.6.166.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Girard, Ségolène. "BEVA® 371-based Synthetic Leather." Journal of Paper Conservation 19, no. 1 (January 2, 2018): 18–32. http://dx.doi.org/10.1080/18680860.2018.1521018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Mountford, David. "British Equine Veterinary Association (BEVA) response." Veterinary Record 182, no. 25 (June 22, 2018): 720. http://dx.doi.org/10.1136/vr.k2673.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Sočivica, Sonja, and Krunoslav Šmit. "Strateško planiranje razvoja grada." Prostor 27, no. 2 (58) (December 23, 2019): 224–35. http://dx.doi.org/10.31522/p.27.2(58).3.

Full text

Abstract:

Iskustva gradova Europske unije u strateškom planiranju razvoja mogu biti primjeri dobre prakse koji su uz razumijevanje konteksta primjenjivi na Zagreb. Analizom podataka i strateških dokumenata uspoređene su razvojne strategije Beča, Budimpešte i Zagreba. Sintezom i vrjednovanjem nalaza formuliran je prijedlog mogućih preporuka za rad na razvojnoj strategiji Grada Zagreba, primjenjivih na širi kontekst strateškog planiranja razvoja gradova.

APA, Harvard, Vancouver, ISO, and other styles

32

Chandler, Norman. "Helen Carpenter retires as BEVA administrative secretary." Equine Veterinary Journal 19, no. 4 (July 1987): 270–71. http://dx.doi.org/10.1111/j.2042-3306.1987.tb01404.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Blaszkowsky, L. S., T. S. Hong, A. X. Zhu, E. L. Kwak, H. J. Mamon, P. C. Shellito, J. C. Cusack, D. Berger, K. Horgan, and D. P. Ryan. "A phase I/II study of bevacizumab (beva), erlotinib (erl), and 5-fluorouracil (5-FU) with concurrent external beam radiation therapy (RT) in locally advanced rectal cancer (LARC)." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 4106. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4106.

Full text

Abstract:

4106 Background: The German Rectal Cancer Study Group established neoadjuvant therapy as a standard of care in patients with T3/T4 rectal cancer. Beva, a vascular endothelial growth factor (VEGF) inhibitor with demonstrated activity in colorectal cancer, and erl, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor may both serve as radiation sensitizers. Methods: Twenty one pts with LARC, defined as T3 or T4 disease by MRI or endorectal ultrasound, were enrolled from May 2006-December 2008. Pts had adequate hepatic, renal and hematopoietic function, and an ECOG performance status of ≤2. Treatment consisted of 5-FU 225 mg/M2/day by continuous infusion for the duration of radiation (50.4 Gy). Beva 5 mg/kg was administered on days 1, 15 and 29. The first cohort received erl 50 mg, the second cohort 100 mg, and third cohort 150 mg daily until completion of radiation. Pts underwent surgery 6–9 weeks following the radiation. The primary endpoints were determination of the maximally tolerated dose (MTD) and pathologic complete response (pCR). Secondary endpoints included toxicity (TOX), local control (LC), progression free survival and median survival. A total of 25 pts will be treated at the MTD. Results: Twenty-one pts began study therapy: 2 withdrew consent prior to completing study therapy, and 2 pts were removed prior to completion for clostridium difficile colitis and cardiac ischemia. No dose limiting toxicities were achieved. Erl 100 mg was chosen as the MTD. Two pts have not yet completed study treatment. Fifteen pts have completed study therapy and have undergone surgery, of whom 7 (47%) have demonstrated a pCR. At a median follow-up of 7 months, there have been no local recurrences in patients who completed study therapy. Grade 3–4 treatment related TOX included: lymphopenia 6 (59%), diarrhea 4 (24%), rash 2(12%), cardiac ischemia 1(6%), transaminitis 1(6%), mucositis 1(6%). One pt developed an anastomotic leak. Conclusions: Beva and erl in combination with infusional 5-FU and RT appears to be a highly active preoperative regimen for locally advanced rectal cancer. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

34

Ruotolo, Roberta Angelica. "Il catalogo muliebre nella Napoli del xvi secolo: un contributo di Benedetto Croce." Quaderns de Filologia - Estudis Literaris 22 (January 7, 2018): 89. http://dx.doi.org/10.7203/qdfed.22.11254.

Full text

Abstract:

La letteratura napoletana è ricca testi incentrati sulle lodi delle donne della città, genere che si vitalizza a contatto con il vivace quadro della società aristocratica del Vicereame. È Benedetto Croce, coadiuvato da Giuseppe Ceci, ad occuparsi tra i primi di quella serie di rime, poemetti, capitoli ed epigrammi incentrati sul catalogo muliebre perché consapevole del loro apporto alla storia del costume e della letteratura nella Napoli del XVI secolo. In Lodi di dame napoletane del secolo decimosesto vengono analizzate quelle opere che la nobiltà napoletana e spagnola si beava di leggere vedendo in queste, e nella raffinata lingua petrarchesca in cui erano scritte, uno specchio della propria elegante condotta.

APA, Harvard, Vancouver, ISO, and other styles

35

Chauché, C., and R. Kennedy. "Science-in-brief: Clinical highlights from BEVA Congress 2016." Equine Veterinary Journal 49, no. 1 (December 15, 2016): 10–12. http://dx.doi.org/10.1111/evj.12644.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

DVM, L. R. Bramlage. "British Equine Veterinary Association (BEVA): thanks for the guidance." Equine Veterinary Education 11, no. 1 (February 1999): 3–4. http://dx.doi.org/10.1111/j.2042-3292.1999.tb00907.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kerbyson, N., K. Davison, and H. Sparks. "Science-in-brief: Clinical highlights from BEVA Congress 2012." Equine Veterinary Journal 45, no. 2 (February 1, 2013): 137–40. http://dx.doi.org/10.1111/evj.12048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Kerbyson, N. "Science-in-brief: Clinical highlights from BEVA Congress 2013." Equine Veterinary Journal 46, no. 2 (February 18, 2014): 131–34. http://dx.doi.org/10.1111/evj.12225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Samalin, Emmanuelle, Tien Tuan Nguyen, Simon Thezenas, Fabienne Portales, Thibault Mazard, Sophie Gourgou, Eric Assenat, and Marc Ychou. "Chemotherapy efficacy in metastatic colorectal cancer (mCRC) patients treated with adjuvant or first-line FOLFOX-based chemotherapy." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e15048-e15048. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15048.

Full text

Abstract:

e15048 Background: Efficacy results of Folfox or Folfiri chemotherapies (CT) are not different as 1st line in mCRC patients, alone or with targeted therapies. No data reported on progression-free survival (PFS) of 1st line Folfiri after Folfox-based adjuvant CT and of 2nd line Folfiri-based CT after a Folfox-based 1st line. The objective was to evaluate the efficacy of a Folfiri-based CT after adjuvant or 1stline Folfox-based treatment. Methods: 210 of 568 pts from a mCRC database were retrospectively selected and divided in 2 cohorts: pts who received adjuvant Folfox then Folfiri as 1st line treatment (n = 76, AdjF) and those treated with Folfox as 1st line treatment then Folfiri 2nd line (n = 134, FFox). PFS1 was the time from beginning of Folfox to 1st progression and PFS2 the time from the Irinotecan-based CT to 2ndprogression. Results: Median age was 62 (22-80). 49.3% pts had synchronous liver (72%) metastases. Primary tumour was right and left colon in 22% and 70% patients. Primary tumour was resected in 91% pts (98.7% and 86.6% in the AdjF and FFox groups, p= 0.003). KRASand BRAF-mutated status were found in 21.8% and 4.7% pts. In the AdjF group, pts received Folfiri as 1st line combined with Bevacizumab (Beva) or anti-EGFR therapy (Cetuximab or Panitumumab) in 70% and 13% cases. In the FFox group, 1st line Folfox-based CT was associated with Beva and anti-EGFRs in 7 and 6% pts, and 2ndline Folfiri-based CT with Beva or Aflibercept in 51 and 4% pts, and with anti-EGFRs in 7.5%. Median duration of a therapeutic line was 5 months (0-29.8). Grade 3-4 toxicities were for the AdjF and FFox groups respectively, diarrhea 13/15%, neutropenia (febrile) 16(7)/37%(1%) and neuropathy 24/18%. Response rates were 55.3% and 68.7% in the AdjF and FFox groups. Median PFS1 were 14 (95%CI:10-16) and 10 (95%CI:8-11) months in the AdjF and FFox groups, and PFS2 10 (95%CI:8-11) and 7 (95%CI:6-9) months, respectively. Median overall survival was 43 (95%CI:39-50) and 33 months (95%CI:26-36) respectively. Conclusions: Results in terms of survival are in favor of the AdjFFox group. It would be interesting to identify a subgroup of pts rapidly progressing after adjuvant Folfox, who might show the same profile than pts in the FFox group.

APA, Harvard, Vancouver, ISO, and other styles

40

Mirović, Dejan. "BRISELSKI SPORAZUM IZ 2013. I BEČKA KONVENCIJA O MEĐUNARODNOM UGOVORNOM PRAVU." Nacionalni interes 18, no. 3 (2013): 135–54. http://dx.doi.org/10.22182/ni.1832013.6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Wann, Daniel L., and Michelle R. Sherman. "The Verbal Aggression of Spectators at Youth Baseball Games: Investigating the Impact of Competition Level, Team Identification, and Fan Dysfunction." Journal of Amateur Sport 5, no. 1 (July 18, 2019): 96–112. http://dx.doi.org/10.17161/jas.v5i1.6761.

Full text

Abstract:

Previous research had found that level of team identification was positively associated with aggression at youth sporting events (Wann, Weaver, Belva, Ladd, & Armstrong, 2015). The current investigation was designed to extend this work by incorporating fan dysfunction into the model (i.e., fans who are confrontational and frequently complain). Spectators at either a recreational or select (i.e., travel) youth baseball game completed a survey packet assessing demographics, team identification with their favorite Major League Baseball team, identification with the youth team, fan dysfunction, and hostile and instrumental verbal aggression directed toward officials and opponents. Results indicated that, contrary to expectations, team identification was not a unique predictor of verbal aggression. Rather, fan dysfunction predicted each form of aggression, aggression toward both targets, and total aggression.

APA, Harvard, Vancouver, ISO, and other styles

42

Carson, D. "BEVA: the next 50 years: who has a crystal ball?" Equine Veterinary Journal 43, no. 5 (August 9, 2011): 505. http://dx.doi.org/10.1111/j.2042-3306.2011.00433.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Freeman, Sarah L., Neal M. Ashton, Yvonne A. Elce, Anna Hammond, Anna R. Hollis, and Greg Quinn. "BEVA primary care clinical guidelines: Wound management in the horse." Equine Veterinary Journal 53, no. 1 (July 17, 2020): 18–29. http://dx.doi.org/10.1111/evj.13289.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Walter, F., F. Petermann, and A. Kobelt. "Erfassung von negativen Antwortverzerrungen – Entwicklung und Validierung des Beschwerdenvalidierungstests BEVA." Die Rehabilitation 55, no. 03 (June 10, 2016): 182–90. http://dx.doi.org/10.1055/s-0042-105939.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Marsh, A., L. Lo, and J. H. Feusner. "Sorafenib (Soraf) and bevacizumab (Beva) for recurrent metastatic hepatoblastoma (HB)." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 9575. http://dx.doi.org/10.1200/jco.2011.29.15_suppl.9575.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Norgren, Jill. "Before It Was Merely Difficult: Belva Lockwood's Life in Law and Politics." Journal of Supreme Court History 24, no. 1 (March 1999): 16–21. http://dx.doi.org/10.1111/j.1540-5818.1999.tb00147.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Weller, Renate. "Renate Weller, President of the British Equine Veterinary Association (BEVA), responds." Veterinary Record 184, no. 24 (June 13, 2019): 743.3–743. http://dx.doi.org/10.1136/vr.l4154.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Horvat-Levaj, Katarina. "Palača Prister arhitekata Hönigsberga i Deutscha i bečka izvorišta neobaroka u zagrebačkoj arhitekturi historicizma." Radovi Instituta za povijest umjetnosti, no. 44/2 (December 2020): 67–86. http://dx.doi.org/10.31664/ripu.2020.44/2.05.

Full text

Abstract:

Neobarokna palača Prister na Strossmayerovu trgu 2 (1893.), projekt Hönigsberga i Deutscha, ističe se urbanističkim smještajem i arhitektonskim obilježjima. S glavnim pročeljem na jednom od trgova perivojne potkove, trokrilnim plastičnim tijelom određuje dvorište u dnu kojeg se uz Petrinjsku ulicu nalazila niža konjušnica s vežom, čime je formiran svojevrsni cour d’honneur. Činjenica da je palača bila rasterećena od kolnog ulaza omogućila je impostaciju raskošnog predvorja i trokrakog stubišta cijelom dubinom pročelnog krila, a navedeno osovinsko rješenje iskazano je na pročelju sceničnim portalom nadvišenim balkonom te elegantnom atikom sa skulpturama. Takvom svojom prostornom organizacijom te unutrašnjom opremom i vanjskom plastikom izdvaja se iz tadašnjega zagrebačkog standarda upućujući na izvore u bečkoj arhitekturi, gdje se školuju projektanti. Danas u funkciji Arhiva i dviju znanstvenih ustanova u sastavu HAZU uključena je u projekt cjelovite obnove nakon potresa 2020. godine, a prateća istraživanja iznijela su na vidjelo nepoznate podatke iz njezine građevne povijesti.

APA, Harvard, Vancouver, ISO, and other styles

49

Metges, J., E. Gamelin, R. Faroux, V. Klein, G. Ganem, J. Douillard, C. Stampfli, S. Corbinais, C. Riche, and F. Grude. "AVASTERB OUEST: A prospective cohort study of unresectable metastatic colon cancer treated successively by FOLFIRI bevacizumab and cetuximab irinotecan." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e15103-e15103. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e15103.

Full text

Abstract:

e15103 Background: Bevacizumab and cetuximab regimen are approuved since 2005 in Europe for Metastatic Colorectal Cancer Patients (MCCP). Very few studies have reported data concerning the sequence (FOLFIRI BEVA and after failure CETUXIMAB- CAMPTO) in MCCP from the real world. Methods: Since 2003, in west of France, (Bretagne-Pays de Loire),a network called OMIT(Observatoire des Médicaments et Innovations Thérapeutiques) directed by Regional Health Agencies has been created. This structure gathered prospectively data from MCCP treated with targeted therapies. Since 2006, a cohort of MCCP treated successively by FOLFIRI BEVACIZUMAB (same protocol : same dose) as first line to progression or unacceptable toxicity and CETUXIMAB- CAMPTO after the first line failure was constitued (AVASTERB cohort). Criteria for initial unresectability of metastic lesions was based on investigator's evaluations during local comitee (surgeons and oncologists). In order to have a large follow up, the 35 first patients of the cohort were studied in this abstract.Age, sex, response rate to the different regimens,secondary metastatic lesion resection, time to progression to the different regimens, follow up and overall survival are the criterias studied. Results: Median age 60 years (49–83), Males : 60%, colon 71%,rectum: 17%, colorectal jonction :12%.Response rate(OR+SD)with Folfiri Bevacizumab : 45.7%. 17% of the patients underwent hepatic surgery with curative intent (all during Folfiri bevacizumab) Time to progression with Bevacizumab : 6 months. Fifty eight percent of the patients are still alive with a median follow up of 25 months (11–29)Median overall survival was not reached.The 12 months and 24 months overall survival rates are respectively 71.4% and 45.7% (date of point: 01/01/2009). Actualisation of the data will be provided during the meeting Conclusions: The results from this prospective unselected cohort of MCCP treated with the sequence FOLFIRI BEVA and after failure CETUX-CAMPTO from the real world show promising TTP, and overall survival. The study of the Kras mutation and others biomarkers could improve these results by personalization of the treatment. This part of our study is actually ongoing. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

50

Houserova, P., V. Kuban, P. Spurny, and P. Habarta. "Determination of total mercury and mercury species in fish and aquatic ecosystems of Moravian rivers." Veterinární Medicína 51, No. 3 (March 19, 2012): 101–10. http://dx.doi.org/10.17221/5527-vetmed.

Full text

Abstract:

Contents of total mercury and mercury species (methylmercury – MeHg, inorganic mercury – Hg<sup>2+</sup>) were determined in four Moravian rivers – Jihlava, Becva, Loucka and Dyje (Czech Republic). Five tissues (muscle, gills, liver, kidney and skin) of chub (Leuciscus cephalus), zoobenthos, sediments and water samples were analyzed. Time stability of samples was also tested. The highest levels of total mercury were determined in muscle tissues of all tested fish. Relative contents of MeHg in muscle tissues of fish ranged from 83.6% to 92.0% of the total mercury contents. The relative contents of MeHg in sediments and in zoobenthos samples correlate very closely (correlation coefficient –0.83). A considerably lower content of MeHg (1.3–11.4%) was found in river sediments compared with lakes. A comparison of observed sampling sites (Vladislav, Hrubsice) proved the adverse effect of industrial contamination on the water ecosystem ofJihlavaRiver and incomplete removal of mercury species in a sewage station

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!